2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Weight Loss
1
Preleukemia
1
Ovarian Neoplasms
1
Osteochondroma
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Nevus, Epithelioid and Spindle Cell
1
Myelodysplastic Syndromes
1
Malnutrition
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioblastoma
1
Giant Cell Tumors
1
Gastrointestinal Neoplasms
1
Fibrosis
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Carcinoma, Merkel Cell
1
Carcinoma, Lobular
1
Carcinoma in Situ
1
Barrett Esophagus
1
Interventions
Cyclophosphamide
211
fludarabine phosphate
185
Azacitidine
160
fludarabine
144
Busulfan
140
Tacrolimus
120
Mycophenolic Acid
112
Cytarabine
111
Whole-Body Irradiation
107
Peripheral Blood Stem Cell Transplantation
99
Antilymphocyte Serum
97
Melphalan
91
Filgrastim
87
Cyclosporine
83
Decitabine
82
Methotrexate
79
venetoclax
63
Granulocyte Colony-Stimulating Factor
56
Radiotherapy
49
Stem Cell Transplantation
48
Thiotepa
47
Cord Blood Stem Cell Transplantation
43
Clofarabine
42
thymoglobulin
41
Specimen Handling
35
Etoposide
35
Methylprednisolone
34
Sirolimus
33
Biopsy
30
Injections
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Sampling Studies
×
Clear all
NCT02809222
2021-04-19
PLASMYC
University Hospital, Tours
Phase NA
Completed
138 enrolled